5 results about "Azilsartan" patented technology

The application relates to a preparation method of an azilsartan solid dispersion and a medicinal composition thereof, and belongs to the technical field of pharmaceutical preparations. A unit dose of the azilsartan solid dispersion comprises azilsartan 20 mg, povidone K30 50-105 mg, sodium acetate trihydrate 4.9-5.7 mg, microcrystalline cellulose 210-270 mg, mannitol 65.6-83.2 mg, and sodium croscarmellose 8-24 mg which is added internally, and the preparation method is wet granulation; a unit dose of the azilsartan medicinal composition comprises the solid dispersion 429.5 mg, sodium croscarmellose 16 mg which is added externally, magnesium stearate 4.5 mg, and film coating premix 18 mg. The preparation process of the azilsartan solid dispersion is simple, almost all pharmaceutical factories have the hardware conditions, and no first and second class organic solvents are used, so that the safety and bioavailability of the azilsartan preparation are effectively improved; the stability of the azilsartan solid dispersion is good, and the dissolution rate and related substances do not obviously decrease after long-time storage.

The invention belongs to the field of organic chemistry, and particularly relates to a low-concentration hydroxylamine composition and a method for preparing an azilsartan intermediate by using the same. The invention provides the hydroxylamine composition with low concentration, high stability and high reaction performance, the hydroxylamine composition has been applied to synthesis of azilsartan, and the azilsartan intermediate synthesized by using the hydroxylamine composition has the advantages of few impurities, high yield, low reaction cost and strong stability, and is suitable for industrial large-scale production.

The invention belongs to the technical field of antigen-antibody detection, and relates to a monoclonal antibody of a non-biphenyl tetrazolsartan drug, a nucleic acid molecule, a detection kit and application thereof. The monoclonal antibody of the non-biphenyl tetrazolsartan medicine comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region comprises a VH-CDR1, a VH-CDR2 and a VH-CDR3, the light chain variable region comprises a VL-CDR1, a VL-CDR2 and a VL-CDR3, the sequence of the VH-CDR1 is as shown in SEQ ID NO.1, and the sequence of the VH-CDR2 is as shown in SEQ ID NO.2. The monoclonal antibody of the non-biphenyl tetrazolsartan medicine has the advantages that the monoclonal antibody of the non-biphenyl tetrazolsartan medicine can be used for preparing the non-biphenyl tetrazolsartan medicine; the monoclonal antibody capable of simultaneously recognizing azilsartan and telmisartan is successfully prepared by taking candesartan as an immunogen and azilsartan as a coating antigen, the azilsartan and telmisartan are specifically detected, and the problem that the two drugs cannot be covered by the existing immunodetection technology is solved.

The present invention relates to a nanosuspension composition comprising i) Azilsartan medoxomil and / or pharmaceutically acceptable salts, ii) copovidone iii) at least one surfactant and iv) at least one pharmaceutically acceptable excipient. The said nanosuspension composition has a desirable pharmacokinetic characteristic properties and stability. The invention further relates to a process for the preparation of said nanocomposition and use thereof for the preparation of medicament, which is useful in the treatment of hypertension.

The invention belongs to the technical field of pesticide preparation and insect prevention and control, and particularly relates to application of Azilsartan as an insect epidermis lipid synthesis inhibitor and in the aspect of pest prevention and control. The invention finds that a small molecule compound Azisartan is an inhibitor of targeted trans-enoyl coenzyme A reductase (TE) for the first time, and results of an in-vitro enzyme activity inhibition test and an insecticidal test prove that the Azisartan can significantly inhibit the activity of a key membrane protein (TE) in an epidermal lipid synthesis pathway of insects, and can be used for preparing a drug for preventing and treating the epidermal lipid synthesis pathway of the insects, so that the drug can be used for preparing a drug for preventing and treating the epidermal lipid synthesis pathway of the insects, and the drug can be used for preventing and treating the epidermal lipid synthesis pathway of the insects and preventing and treating the epidermal lipid synthesis pathway of the insects. And the insecticidal composition has obvious insecticidal activity on Asiatic corn borer, plutella xylostella, tenebrio molitor and tribolium cavaleriei. Meanwhile, the small molecule compound Azilsartan provides a research basis for research and development of insecticides, and is beneficial to research and development of green pesticides.